BACKED BY CLINICAL RESEARCH
The Research Behind Our Products.
Our claims are tested, not assumed. Atrantil and Re:flux have been evaluated across multiple clinical studies, including independent research conducted entirely outside of KBS, measuring real effects in real patients.
Independent Open-Label Study, Northwestern University Feinberg School of Medicine
An independent, open-label clinical trial led by Darren Brenner, MD, FACG, AGAF, conducted at Northwestern University and independently of KBS Research, evaluating Atrantil in patients with methane-predominant intestinal overgrowth.
- Single-arm, open-label design, 40 participants, four weeks of treatment
- Measured changes in pain, bloating, distention, and discomfort, plus quality of life and methane breath levels
- Enrolled with minimal exclusion criteria to reflect real-world patients
- Registered as NCT04755673 (completed 2022)
Randomized, Double-Blind, Placebo-Controlled Trial
A two-week, double-blind, placebo controlled pilot study evaluating the Atrantil blended extract against placebo in patients with IBS-C.
- Randomized, double-blind, placebo-controlled design, 16 participants
- Significant improvement versus placebo in constipation (p=0.0034) and bloating (p<0.001)
- Combined symptom score improved (p<0.001)
- No adverse events reported
- Journal of Gastroenterology and Hepatology Research, September 21, 2015
Retrospective Case Series
A real-world chart analysis evaluating Atrantil in IBS-C patients who had not responded to previous therapies
- Retrospective case series, 24 patients, two weeks
- 88% of patients improved across abdominal pain, bloating, and constipation
- All three symptoms improved significantly from baseline
- Real-world patients who had failed prior therapies
- World Journal of Gastrointestinal Pharmacology and Therapeutics, August 6, 2016
Retrospective Chart Analysis,
Chronic GERD (Re:flux)
A retrospective chart analysis evaluating the Re:flux polyphenol formulation in patients with endoscopically confirmed chronic GERD, compared with usual care.
- Retrospective chart analysis, four weeks; nutraceutical group (n=47) versus usual care (n=25)
- 91.5% had clinically meaningful improvement (75% or greater) in reflux symptoms
- 81% reported complete symptom resolution, versus 16% on usual care
- Of patients who had been on acid-blocking medication, 79.3% remained off it through the four weeks
- Patients reporting bloating at baseline showed improvement by week 4
- Open Journal of Gastroenterology, March 17, 2026
